Table 3.

Risk factors for atherosclerosis and autoantibodies in migraineurs and controls

	Control group	Migraine patients	p
Total cholesterol (mg/dL)	147 ± 35	217 ± 42	<0.001
TAG (mg/dL)	84 ± 22	103 ± 46	0.025
HDL (mg/dL)	66 ± 21	67 ± 13	0.79
LDL (mg/dL)	100 ± 18	135 ± 37	<0.001
Homocysteine (mmol/L)	12.82 ± 3.98	13.2 ± 5.2	0.73
Lp (a) (g/L) median (interquartile range)	0.065 (0.03–0.10)	0.09 (0.04–0.21)	0.15
Anti–nuclear antibodies Anti–dsDNA Anti-MPO pANCA Anti-Pr3 c-ANCA ASMA APCA AMA HMA Anti-cardiolipin IgM (U/mL) Anti-cardiolipin IgG (U/mL)	Negative in all patients Negative in all patients Negative in all patients Negative in all patients Negative in all patients Negative in all patients Negative in all patients Negative in all patients 1.30 (0.80–1.60) 0.60 (0.30–1.40)	Negative in all subjects Negative in all subjects Negative in all subjects Negative in all subjects Negative in all patients Negative in all patients Negative in all patients Negative in all patients 1.10 (0.90–1.80) 0.40 (0.10–0.60)

Anti-dsDNA anti-double stranded DNA, anti-MPO/pANCA anti-myeloperoxidase/perinuclear pattern anti-neutrophil cytoplasm autoantibodies, Anti-Pr3/c-ANCA anti-proteinase 3/cytoplasmic pattern anti-neutrophil cytoplasm autoantibodies, ASMA anti-smooth muscle antibodies, APCA anti-parietal cell antibodies, AMA antimitochondrial antibodies, HMA hepatocyte membrane antibodies